Antibody Drug Conjugates (ADCS) Market

Market Synopsis:

Global Antibody Drug Conjugates (ADCS) market is valued at USD 4.75 Billion in 2022 and is projected to attain a value of USD 18.84 Billion by 2030 at a CAGR of 18.80% during the forecast period, 2022–2028. Antibody Drug Conjugates (ADCS) are highly targeted bio-pharmaceutical therapies that combine monoclonal antibodies specific for surface antigens found on specific tumor cells with extremely potent anticancer chemicals coupled by chemical linkers. Antibody Drug Conjugates (ADCS), in simple terms, provide "deactivated" cytotoxins to cancer cells. Internalization allows the cytotoxin to restore its full cancer-killing cytotoxic activity inside the tumor cell. As a result, cell death is hastened. There are thousands of cellular poisons available, many of which are obtained from natural sources or chemically produced, but only a few are acceptable for use in Antibody Drug Conjugates (ADCS). Clinically approved chemotherapeutic medicines like doxorubicin and methotrexate were used to develop the first Antibody Drug Conjugates (ADCS).

The COVID-19 pandemic has wreaked havoc on the global population and economy. Across the globe, the COVID-19 pandemic caused substantial obstacles to the health-care system. Due to the imposition of lockdown, which resulted in trade restrictions and supply chain disruptions, it had a negative impact on the growth of the Antibody Drug Conjugates (ADCS) market for a short period of time.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Significant Investment in Research and Development

ADCs are currently recognized as a potent class of targeted anticancer medicines, with the potential to treat a number of additional disease indications, with six licenced medications. The success of such products, according to the report, can be linked to their ability to effectively identify and destroy disease-associated cells/pathogens while posing a far lower risk of treatment-related side effects.

Around 250 antibody drug conjugates are being developed right now. According to the data, roughly 40% of these are in the clinical stage of development, and 60% of clinical stage therapeutic candidates are for the treatment of solid tumors. Around 40 percent of these intellectual property documents were filed granted in the US; other key regions with significant intellectual capital include Japan, Canada, China, Korea and Taiwan.

Strict Regulatory Requirements and Unstable Raw Material Cost

The cost of various raw materials is rising due to market conditions, and purchasers are currently being inundated with price hikes across multiple categories. The cost of raw materials is rising, posing issues for enterprises throughout their supply chains. Manufacturers are still grappling with the two supply chain bottlenecks that plagued the industry throughout the pandemic: sluggish supplier deliveries and labor availability, while costs continue to rise. Stringent regulatory compliance for specialist medical protective clothing goods, on the other hand, would stymie worldwide medical protective clothing demand.

Market Segmentation:

The Global Antibody Drug Conjugates (ADCS) Market has been segmented by Application into Breast Cancer, Urothelial Cancer & Bladder Cancer and Other Cancer. By Technology, into Cleavable Linker, Non-cleavable Linker and Linker-less. Based on Region, the Antibody Drug Conjugates (ADCS) Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

North America to Continue Dominating the Antibody Drug Conjugates (ADCS) Market

North America, Europe, and Asia Pacific accounted for the greatest proportion of the Antibody Drug Conjugates (ADCS) market in 2021. Factors such as the increase in the number of well-established Antibody Drug Conjugates (ADCS) companies and research institutes in the United States and Canada, a large number of ongoing research studies, and the overall growth of the healthcare sector on a global scale are among the few factors expected to contribute to the market's growth. The regional market growth can be attributed to expanding geriatric populace, increasing surgical procedures, expanding and presence of established healthcare infrastructure. One of the primary causes leading to the growing demand for Antibody Drug Conjugates (ADCS) techniques and technologies among academic and research organisations, as well as healthcare firms in North America, is increased R&D spending.

Key Players:

Some of the major players in the market are Takeda Pharmaceutical Company Ltd. (Japan), F. Hoffmann-La Roche Ltd. (US), Pfizer Inc. (US), AstraZeneca (Sweden), Gilead Sciences Inc. (US), Astellas Pharma (Japan), Seagen Inc. (US), Daiichi Sankyo Company Ltd. (Japan), GlaxoSmithKline PLC (UK), ADC Therapeutics (Switzerland)

The Antibody Drug Conjugates (ADCS) market is segmented as follows:

The Antibody Drug Conjugates (ADCS) market scope can be tabulated as below: